KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Accumulated Expenses: 2020-2025

Historic Accumulated Expenses for Recursion Pharmaceuticals (RXRX) over the last 5 years, with Sep 2025 value amounting to $53.1 million.

  • Recursion Pharmaceuticals' Accumulated Expenses rose 30.80% to $53.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $53.1 million, marking a year-over-year increase of 30.80%. This contributed to the annual value of $81.9 million for FY2024, which is 75.56% up from last year.
  • Recursion Pharmaceuticals' Accumulated Expenses amounted to $53.1 million in Q3 2025, which was down 17.39% from $64.3 million recorded in Q2 2025.
  • Recursion Pharmaceuticals' Accumulated Expenses' 5-year high stood at $81.9 million during Q4 2024, with a 5-year trough of $11.1 million in Q1 2021.
  • Its 3-year average for Accumulated Expenses is $45.5 million, with a median of $40.6 million in 2024.
  • Data for Recursion Pharmaceuticals' Accumulated Expenses shows a peak YoY soared of 208.37% (in 2021) over the last 5 years.
  • Over the past 5 years, Recursion Pharmaceuticals' Accumulated Expenses (Quarterly) stood at $32.3 million in 2021, then rose by 1.77% to $32.9 million in 2022, then soared by 41.73% to $46.6 million in 2023, then spiked by 75.56% to $81.9 million in 2024, then spiked by 30.80% to $53.1 million in 2025.
  • Its Accumulated Expenses was $53.1 million in Q3 2025, compared to $64.3 million in Q2 2025 and $56.8 million in Q1 2025.